Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-17T16:18:44.029Z Has data issue: false hasContentIssue false

Chapter 20 - Autoimmune Hepatitis in Children

from Section III - Hepatitis and Immune Disorders

Published online by Cambridge University Press:  19 January 2021

By
Nanda Kerkar  and
Cara L. Mack
Edited by
Frederick J. Suchy ,
Ronald J. Sokol  and
William F. Balistreri
Edited in association with
Jorge A. Bezerra ,
Cara L. Mack  and
Benjamin L. Shneider
Frederick J. Suchy
Affiliation:
University of Colorado, Children’s Hospital Colorado, Aurora
Ronald J. Sokol
Affiliation:
University of Colorado, Children’s Hospital Colorado, Aurora
William F. Balistreri
Affiliation:
Cincinnati Children’s Hospital Medical Center, Cincinnati
Jorge A. Bezerra
Affiliation:
Cincinnati Children’s Hospital Medical Center, Cincinnati
Cara L. Mack
Affiliation:
University of Colorado, Children’s Hospital Colorado, Aurora
Benjamin L. Shneider
Affiliation:
Texas Children’s Hospital, Houston
Get access

Summary

Autoimmune hepatitis (AIH) is a progressive inflammatory disorder of unknown etiology, characterized histologically by interface hepatitis, serologically by the presence of non-organ specific autoantibodies, biochemically by elevated aminotransferases and serum IgG, and clinically by response to immunosuppressive treatment in the absence of other known causes of liver disease [1].

Type
Chapter
Information
Liver Disease in Children , pp. 321 - 332
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Mieli-Vergani, G, Vergani, D. Autoimmune hepatitis. Nat Rev Gastroenterol Hepatol 2011;8(6):320–9.Google Scholar
Whittingham, S, et al. Smooth muscle autoantibody in “autoimmune” hepatitis. Gastroenterology 1966;51(4):499–505.Google Scholar
De Groote, J, et al. A classification of chronic hepatitis. Lancet 1968;2(7568):626–8.Google ScholarPubMed
Johnson, PJ, McFarlane, IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18(4):998–1005.Google Scholar
Palle, SK, et al. Racial disparities in presentation and outcomes of paediatric autoimmune hepatitis. Liver Int 2019;39(5):976–84.CrossRefGoogle ScholarPubMed
Czaja, AJ. Global disparities and their implications in the occurrence and outcome of autoimmune hepatitis. Dig Dis Sci 2017;62(9):2277–92.Google Scholar
Mieli-Vergani, G, et al. Autoimmune hepatitis. Nat Rev Dis Primers 2018;4:18017.CrossRefGoogle ScholarPubMed
Webb, GJ, et al. Cellular and molecular mechanisms of autoimmune hepatitis. Annu Rev Pathol 2018;13:247–92.CrossRefGoogle ScholarPubMed
Longhi, MS, et al. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun 2010;34(1):7–14.Google Scholar
Than, NN, Jeffery, HC, Oo, YH. Autoimmune hepatitis: progress from global immunosuppression to personalised regulatory T cell therapy. Can J Gastroenterol Hepatol 2016;2016:7181685.Google Scholar
Mieli-Vergani, G, Vergani, D. Autoimmune hepatitis in children: what is different from adult AIH? Semin Liver Dis 2009;29(3):297–306.Google Scholar
Invernizzi, P, Lleo, A, Podda, M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis 2007;27(2):161–72.Google Scholar
Czaja, AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci 2010;55(8):2144–61.CrossRefGoogle ScholarPubMed
Karlsen, TH, Chung, BK. Genetic risk and the development of autoimmune liver disease. Dig Dis 2015;33(Suppl 2):13–24.Google Scholar
Kerkar, N. (2019). Autoimmune hepatitis in special populations: in pediatrics and across different ethnicities/races, in Clinical Liver Disease (pp. 37–40). Oxford: Wiley.Google Scholar
Jaeckel, E, Hardtke-Wolenski, M, Fischer, K. The benefit of animal models for autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011;25(6):643–51.CrossRefGoogle ScholarPubMed
Lapierre, P, et al. A murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology 2004;39(4):1066–74.Google Scholar
Christen, U, Hintermann, E. Immunopathogenic mechanisms of autoimmune hepatitis: how much do we know from animal models? Int J Mol Sci 2016;17(12). https://doi.org/10.3390/ijms17122007Google Scholar
Hennes, EM, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1):169–76.Google Scholar
Arcos-Machancoses, JV, et al. Accuracy of the simplified criteria for autoimmune hepatitis in children: systematic review and decision analysis. J Clin Exp Hepatol 2019;9(2):147–55.Google Scholar
Czaja, AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011;56(4):958–76.Google Scholar
Kerkar, N, Miloh, T. Sclerosing cholangitis: pediatric perspective. Curr Gastroenterol Rep 2010;12(3):195–202.CrossRefGoogle ScholarPubMed
Weiler-Normann, C, Schramm, C. Drug-induced liver injury and its relationship to autoimmune hepatitis. J Hepatol 2011;55(4):747–9.Google Scholar
Zen, Y, Yeh, MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol 2018;31(6):965–73.CrossRefGoogle ScholarPubMed
Mathis, D, Benoist, C. Aire. Annu Rev Immunol 2009;27:287–312.Google Scholar
Davies, EG, Thrasher, AJ. Update on the hyper immunoglobulin M syndromes. Br J Haematol 2010;149(2):167–80.Google Scholar
Cook, GC, Mulligan, R, Sherlock, S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971;40(158):159–85.Google Scholar
Rumbo, C, et al. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. J Pediatr Gastroenterol Nutr 2002;35(3):391–8.Google Scholar
Sheiko, MA, et al. Outcomes in pediatric autoimmune hepatitis and significance of azathioprine metabolites. J Pediatr Gastroenterol Nutr 2017;65(1):80–5.CrossRefGoogle ScholarPubMed
Dunkin, D, et al. Allopurinol salvage therapy in pediatric overlap autoimmune hepatitis-primary sclerosing cholangitis with 6-MMP toxicity. J Pediatr Gastroenterol Nutr 2010;51(4):524–6.Google Scholar
Pratt, DS, Flavin, DP, Kaplan, MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996;110(1):271–4.Google Scholar
Gregorio, GV, et al. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 2002;35(8):515–19.Google Scholar
Czaja, AJ, Manns, MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010;139(1):58–72 e4.Google Scholar
Lohse, AW, Gil, H. Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment. J Hepatol 2011;54(4):837–9.Google Scholar
Manns, MP, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010;139(4):1198–206.Google Scholar
Woynarowski, M, et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr 2013;163(5):1347–53 e1.CrossRefGoogle ScholarPubMed
Zizzo, AN, et al. Second-line agents in pediatric patients with autoimmune hepatitis: a systematic review and meta-analysis. J Pediatr Gastroenterol Nutr 2017;65(1):6–15.CrossRefGoogle ScholarPubMed
Kerkar, N. Pediatric autoimmune hepatitis: what do you do when first-line therapy fails? J Pediatr Gastroenterol Nutr 2017;65(1):2–4.Google Scholar
Richardson, PD, James, PD, Ryder, SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33(3):371–5.Google Scholar
Aw, MM, et al. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009;51(1):156–60.Google Scholar
Yu, ZJ, et al. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis. Eur J Gastroenterol Hepatol 2019;31(7):873–7.Google Scholar
Sherman, KE, Narkewicz, M, Pinto, PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994;21(6):1040–7.CrossRefGoogle ScholarPubMed
Hyams, JS, Ballow, M, Leichtner, AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987;93(4):890–3.Google Scholar
De Lemos-Bonotto, M, et al. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment. Eur J Gastroenterol Hepatol 2018;30(2):212–16.Google Scholar
Hanouneh, M, et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis. Scand J Gastroenterol 2019;54(1):76–80.Google Scholar
Marlaka, JR, et al. Tacrolimus without or with the addition of conventional immunosuppressive treatment in juvenile autoimmune hepatitis. Acta Paediatr 2012;101(9):993–9.Google Scholar
Efe, C, et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis. Dig Dis Sci 2018;63(5):1348–54.Google Scholar
Mieli-Vergani, G, et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr 2018;66(2):345–60.Google Scholar
Cuarterolo, ML, et al. Immunosuppressive therapy allows recovery from liver failure in children with autoimmune hepatitis. Clin Gastroenterol Hepatol 2011;9(2):145–9.CrossRefGoogle ScholarPubMed
Rahim, MN, et al. Acute severe autoimmune hepatitis: corticosteroids or liver transplantation? Liver Transpl 2019;25(6):946–59.CrossRefGoogle ScholarPubMed
Ichai, P, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13(7):996–1003.Google Scholar
Di Giorgio, A, et al. Fulminant hepatic failure of autoimmune aetiology in children. J Pediatr Gastroenterol Nutr 2015;60(2):159–64.Google Scholar
Greene, MT, Whitington, PF. Outcomes in pediatric autoimmune hepatitis. Curr Gastroenterol Rep 2009;11(3):248–51.CrossRefGoogle ScholarPubMed
Montano-Loza, AJ, Carpenter, HA, Czaja, AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007;102(5):1005–12.Google Scholar
Al-Chalabi, T, et al. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008;48(1):140–7.Google Scholar
Radhakrishnan, KR, et al. Autoimmune hepatitis in children–impact of cirrhosis at presentation on natural history and long-term outcome. Dig Liver Dis 2010;42(10):724–8.Google Scholar
Yeoman, AD, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008;48(3):863–70.Google Scholar
Kerkar, N, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351(9100):409–13.Google Scholar
Demetris, AJ, et al. Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant 2016;16(10):2816–35.Google Scholar
Kerkar, N, Vergani, D. De novo autoimmune hepatitis: is this different in adults compared to children? J Autoimmun 2018;95:26–33.Google Scholar
Kerkar, N, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005;5(5):1085–9.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×